Table 3.
Measure | Controls (AHI < 10) | OSA (15 ≤ AHI ≤ 75) | p § | ||
---|---|---|---|---|---|
N † | Estimate (95% CI)‡ | N † | Estimate (95% CI)‡ | ||
Combined | |||||
Average IMT (mm) | 32 | 0.66 (0.61, 0.71) | 68 | 0.69 (0.66, 0.71) | .386 |
Maximum IMT (mm) | 32 | 0.70 (0.65, 0.75) | 68 | 0.72 (0.69, 0.75) | .513 |
Minimum IMT (mm) | 32 | 0.61 (0.57, 0.66) | 68 | 0.65 (0.62, 0.68) | .199 |
Diameter (mm) | 32 | 7.06 (6.85, 7.27) | 68 | 7.20 (7.06, 7.33) | .317 |
Arterial wall mass | 32 | 0.79 (0.73, 0.86) | 68 | 0.85 (0.80, 0.89) | .221 |
Circumferential stress | 32 | 61.48 (56.82, 66.13) | 65 | 62.18 (59.13, 65.22) | .818 |
Right side | |||||
Average IMT (mm) | 32 | 0.65 (0.60, 0.70) | 68 | 0.69 (0.66, 0.72) | .202 |
Maximum IMT (mm) | 32 | 0.69 (0.64, 0.74) | 68 | 0.73 (0.69, 0.76) | .263 |
Minimum IMT (mm) | 32 | 0.6 (0.55, 0.65) | 68 | 0.66 (0.62, 0.69) | .107 |
Diameter (mm) | 32 | 7.15 (6.90, 7.39) | 68 | 7.24 (7.08, 7.39) | .569 |
Arterial wall mass | 32 | 0.79 (0.72, 0.87) | 68 | 0.86 (0.81, 0.91) | .171 |
Circumferential stress | 32 | 63.59 (58.79, 68.40) | 65 | 61.52 (58.36, 64.68) | .509 |
Left side | |||||
Average IMT (mm) | 31 | 0.67 (0.62, 0.73) | 67 | 0.68 (0.65, 0.72) | .817 |
Maximum IMT (mm) | 31 | 0.72 (0.66, 0.77) | 67 | 0.72 (0.68, 0.75) | .987 |
Minimum IMT (mm) | 31 | 0.63 (0.57, 0.68) | 67 | 0.65 (0.61, 0.68) | .558 |
Diameter (mm) | 31 | 6.95 (6.73, 7.17) | 67 | 7.15 (7.01, 7.29) | .156 |
Arterial wall mass | 31 | 0.79 (0.72, 0.87) | 67 | 0.84 (0.79, 0.89) | .391 |
Circumferential stress | 31 | 59.26 (53.33, 65.19) | 64 | 62.79 (58.94, 66.63) | .362 |
AHI = apnea-hypopnea index; CI = confidence interval; IMT = intima-media thickness; OSA = obstructive sleep apnea.
*Nonobese defined as a waist circumference ≤ 107 cm in men or ≤ 96 cm in women;
†Sample size with available data;
‡Linear (right, left) or mixed (combined) model derived estimated value of measure at baseline, adjusted for site, BMI, age, gender, race, current smoking status, current alcohol use, HDL, lipid lowering medication use, number of antihypertensive medications (0, 1 or ≥2), and glucose;
‡ p-value comparing controls and OSA at baseline.